EVIDENCE LIBRARY
Poststroke Pneumonia Cohort Found a Benzodiazepine Association Without a Clear Cumulative-Dose Gradient
A matched claims study associated benzodiazepine use after stroke with pneumonia developing more than a month later. It could not identify aspiration as the mechanism.
A matched claims study associated benzodiazepine use after stroke with pneumonia developing more than a month later. It could not identify aspiration as the mechanism.
The defined population and outcome
The researchers matched 3,758 poststroke benzodiazepine users with 3,758 nonusers. Follow-up averaged 4.4 years, with pneumonia counted beyond the first month after stroke.
The adjusted hazard ratio was 2.21, with a ninety-five-percent confidence interval of 1.97–2.48. Cumulative-dose subgroups all showed elevated estimates, but not a clear increasing dose-effect pattern.
Why mechanism remains uncertain
The claims data lacked detailed clinical examination, lifestyle, and laboratory information. Investigators could not determine which pneumonias involved aspiration, so a sedative-aspiration explanation remained plausible rather than proven.
Prescription indications, stroke-related vulnerability, and other unmeasured factors may influence both treatment and infection. Matching does not remove all residual confounding or validate every diagnostic code.
Application to testimony
Do not apply this chronic-onset association directly to an immediate perioperative aspiration event. Preserve the poststroke population and timing definition. The paper supports investigating a possible relationship, but cannot prove that a benzodiazepine caused an individual infection or quantify its contribution without case-specific evidence.
Source paper
Original analysis of the supplied journal article, identified as PMC6347861.